An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs ATA 188 Allogeneic (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Atara Biotherapeutics
- 19 Oct 2017 Status changed from not yet recruiting to recruiting according to an Atara Bio media release.
- 17 Oct 2017 According to an Atara Bio media release, US sites are expected to open for enrollment in 2018.
- 16 Oct 2017 According to an Atara Bio media release, this trial is expected to initiate in the fourth quarter of 2017.